Genelux Corporation

Genelux Corporation is a privately held, biopharmaceutical clinical stage company that was founded in 2001.[1][2] The main focus of Genelux is oncolytic immunotherapy based on attenuated, genetically engineered oncolytic viruses as therapeutic agent.

Genelux Corporation
TypePrivate
IndustryBiopharmaceuticals
Headquarters
3030 Bunker Hill St, San Diego, California
,
U.S.
Number of locations
3 (USA (2), Germany)
ProductsGL-ONC1, V-VET1
Number of employees
~16
Websitewww.genelux.com

In 2013 Genelux obtained the San Diego Business Journal Innovation Award in the category of Medical Research.[3]

Locations

Genelux Corp. is headquartered in San Diego, California, with a business office in Redlands, California.[1]

GL-ONC1

Genelux’s lead oncology compound is GL-ONC1 (clinical grade formulation of the laboratory strain GLV-1h68), an oncolytic vaccinia virus. In November 2013 GL-ONC1 has been selected as one of the "Top 10 Oncology Projects to Watch" by Elsevier Business Intelligence.[4] Currently, GL-ONC1 is being evaluated in human clinical Phase I/II studies, including an ongoing Phase II trial in recurrent ovarian cancer.[5] In those studies GL-ONC1 was shown to be well tolerated and evidence of tumor colonization and indications for therapeutic efficacy were observed.[6][7][8]

Veterinary lead compound

In addition to GL-ONC1, Genelux sponsors a veterinary trial in dogs with cancer that is conducted at the CVS Angel Care Cancer Center in Carlsbad, California.[9] The dogs are treated with V-VET1, a non-genetically modified vaccinia virus isolate (laboratory name LIVP6.1.1) with an inactive thymidine kinase gene.[10]

Pipeline

The preclinical pipeline of Genelux includes numerous genetically modified vaccinia virus strains with transgenes encoding for reporter proteins for deep tissue imaging,[11][12][13] angiogenesis modifying proteins,[14] radiosensitzing proteins,[15] prodrug converting enzymes,[16][17] biomarkers[18] and immunomodulatory proteins.[19]

References
  1. "Genelux". genelux.com.
  2. "Genelux Corp. may be on the verge a breakthrough". highbeam.com. Archived from the original on 2016-04-19.
  3. "Innovation Awards 2013 SDBJ Supplement - San Diego Business Journal". sdbj.com.
  4. "Genelux, a Leader in the Emerging Oncolytic Virotherapy Field, Receives Significant Industry Honor from Elsevier Business Intelligence, Identifying GL-ONC1 as One of 2013's 'Top Oncology Projects to Watch'" (Press release). Genelux. November 18, 2013. Retrieved July 18, 2018.
  5. "Search of: GL-ONC1 - List Results - ClinicalTrials.gov". clinicaltrials.gov.
  6. "Phase I clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging. - 2012 ASCO Annual Meeting - Abstracts - Meeting Library". asco.org.
  7. Mell, Loren K.; Yu, Yong A.; Brumund, Kevin T.; Daniels, Gregory A.; Advani, Sunil J.; Weisman, Robert A.; Sanghvi, Parag R.; Martin, Peter J.; Wright, Mary E.; Onyeama, Sara-Jane; Zhang, Qian; Pold, Anu; Chamberlin, Terry; Frentzen, Alexa; Szalay, Aladar A (2015). "Phase I trial of intravenous attenuated vaccinia virus (GL-ONC1) with concurrent chemoradiotherapy (CRT) for locoregionally advanced head and neck carcinoma". Journal of Clinical Oncology. 33 (15 Suppl): 6026. doi:10.1200/jco.2015.33.15_suppl.6026.
  8. "Genelux Announces Positive Phase 1 Data for Viral-Based Cancer Therapy". Drug Discovery & Development.
  9. Clinical Trials & Treatments at the CVS Angel Care Cancer Center
  10. Gentschev I, Patil SS, Adelfinger M, Weibel S, Geissinger U, Frentzen A, et al. (2013). "Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy". Bioengineered. 4 (2): 84–9. doi:10.4161/bioe.22462. PMC 3609626. PMID 23093804.
  11. Haddad D, Chen NG, Zhang Q, Chen CH, Yu YA, Gonzalez L, et al. (2011). "Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus". J Transl Med. 9: 36. doi:10.1186/1479-5876-9-36. PMC 3080806. PMID 21453532.
  12. Brader P, Kelly KJ, Chen N, Yu YA, Zhang Q, Zanzonico P, et al. (2009). "Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene". Clin Cancer Res. 15 (11): 3791–801. doi:10.1158/1078-0432.CCR-08-3236. PMC 5503149. PMID 19470726.
  13. Stritzker J, Kirscher L, Scadeng M, Deliolanis NC, Morscher S, Symvoulidis P, et al. (2013). "Vaccinia virus-mediated melanin production allows MR and optoacoustic deep tissue imaging and laser-induced thermotherapy of cancer". Proc Natl Acad Sci U S A. 110 (9): 3316–20. Bibcode:2013PNAS..110.3316S. doi:10.1073/pnas.1216916110. PMC 3587225. PMID 23401518.
  14. Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, Raab V, et al. (2009). "Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy". Proc Natl Acad Sci U S A. 106 (31): 12915–20. Bibcode:2009PNAS..10612915F. doi:10.1073/pnas.0900660106. PMC 2722284. PMID 19617539.
  15. Buckel L, Advani SJ, Frentzen A, Zhang Q, Yu YA, Chen NG, et al. (2013). "Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium". Int J Cancer. 133 (12): 2989–99. doi:10.1002/ijc.28296. PMID 23729266.
  16. Seubert CM, Stritzker J, Hess M, Donat U, Sturm JB, Chen N, et al. (2011). "Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA". Cancer Gene Ther. 18 (1): 42–52. doi:10.1038/cgt.2010.49. PMC 3007590. PMID 20829890.
  17. Ruiz-Hernández E, Hess M, Melen GJ, Theek B, Talelli M, Shi Y, et al. (2014). "PEG-pHPMAm-based polymeric micelles loaded with doxorubicin-prodrugs in combination antitumor therapy with oncolytic vaccinia viruses". Polym Chem. 5 (5): 1674–1681. doi:10.1039/C3PY01097J. PMC 3836408. PMID 24518685.
  18. Hess M, Stritzker J, Härtl B, Sturm JB, Gentschev I, Szalay AA (2011). "Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapies". J Transl Med. 9: 172. doi:10.1186/1479-5876-9-172. PMC 3207905. PMID 21989091.
  19. Sturm JB, Hess M, Weibel S, Chen NG, Yu YA, Zhang Q, et al. (2012). "Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapy". J Transl Med. 10: 9. doi:10.1186/1479-5876-10-9. PMC 3268093. PMID 22236378.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.